Akt Inhibitor XVI, AT7867

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Grimshaw, K.M., et al. 2010. Mol. Cancer Ther.9, 1100.
Saxty, G., et al. 2007. J. Med. Chem.50, 2293.

Packaged under inert gas

Toxicity: Standard Handling (A)

A cell-permeable pyrazolo compound that acts as a potent inhibitor against Akt (IC₅₀ = 32, 17, and 47 nM against Akt1, Akt2, and Akt3, respectively), PKA (IC₅₀ = 20 nM), and p70S6K (IC₅₀ = 85 nM) in an ATP-competitive manner (K_i = 18 nM using AKT2), with much reduced activity toward RSK1 (IC₅₀ >100 nM) and a panel of 13 other cellular kinases (IC₅₀ >1 µM), including PDK1, PI 3-Kβ, SGK, GSK-3β, and MEK1. Shown to effectively reduce the phosphorylation levels of GSK-3β, S6R, and FKHRL1 (IC₅₀ range from 2.08 to 4.45 µM against GSK-3β pSer⁹ level), as well as inhibit the proliferation (IC₅₀ range from 0.94 to 11.86 µM) of cancer cells exhibiting constitutive Akt pathway activation, including the PTEN-deficient MES-SA uterine sarcoma and U87MG glioblastoma cell lines. AT7867 treatments via i.p. or p.o. (20 mg/kg and 90 mg/kg, respectively, once every 3 days) are also reported to result in Akt pathway and tumor growth inhibition in mice bearing MES-SA (~40% of untreated control on day 10 by i.p. or p.o.) or U87MG (~50% of untreated control on day 10 by i.p.) xenograft in vivo.